{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:32:10Z","timestamp":1792740730785,"version":"4.5.0"},"reference-count":64,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5,1]]},"abstract":"<jats:p>Context. The US Food and Drug Administration approved a meningococcal conjugate A\/C\/Y\/W-135 vaccine (MCV-4) for use in persons aged 11 to 55 years in January, 2005; licensure for use in younger age groups is expected in 2 to 4 years.<\/jats:p><jats:p>Objective. To evaluate and compare the projected health and economic impact of MCV-4 vaccination of US adolescents, toddlers, and infants.<\/jats:p><jats:p>Design. Cost-effectiveness analysis from a societal perspective based on data from Active Bacterial Core Surveillance (ABCs) and other published and unpublished sources. Sensitivity analyses in which key input measures were varied over plausible ranges were performed.<\/jats:p><jats:p>Setting and Patients. A hypothetical 2003 US population cohort of children 11 years of age and a 2003 US birth cohort.<\/jats:p><jats:p>Interventions. Hypothetical routine vaccination of adolescents (1 dose at 11 years of age), toddlers (1 dose at 1 year of age), and infants (3 doses at 2, 4, and 6 months of age). Each vaccination scenario was compared with a \u201cno-vaccination\u201d scenario.<\/jats:p><jats:p>Main Outcome Measures. Meningococcal cases and deaths prevented, cost per case prevented, cost per life-year saved, and cost per quality-adjusted life-year saved.<\/jats:p><jats:p>Results. Routine MCV-4 vaccination of US adolescents (11 years of age) would prevent 270 meningococcal cases and 36 deaths in the vaccinated cohort over 22 years, a decrease of 46% in the expected burden of disease. Before program costs are counted, adolescent vaccination would reduce direct disease costs by $18 million and decrease productivity losses by $50 million. At a cost per vaccination (average public-private price per dose plus administration fees) of $82.50, adolescent vaccination would cost society $633000 per meningococcal case prevented and $121000 per life-year saved. Key variables influencing results were disease incidence, case-fatality ratio, and cost per vaccination. The cost-effectiveness of toddler vaccination is essentially equivalent to adolescent vaccination, whereas infant vaccination would be much less cost-effective.<\/jats:p><jats:p>Conclusions. Routine MCV-4 vaccination of US children would reduce the burden of disease in vaccinated cohorts but at a relatively high net societal cost. The projected cost-effectiveness of adolescent vaccination approaches that of recently adopted childhood vaccines under conditions of above-average meningococcal disease incidence or at a lower cost per vaccination.<\/jats:p>","DOI":"10.1542\/peds.2004-2514","type":"journal-article","created":{"date-parts":[[2005,5,2]],"date-time":"2005-05-02T19:38:07Z","timestamp":1115062687000},"page":"1220-1232","source":"Crossref","is-referenced-by-count":107,"title":["Cost-Effectiveness of Conjugate Meningococcal Vaccination Strategies in the United States"],"prefix":"10.1542","volume":"115","author":[{"given":"Colin W.","family":"Shepard","sequence":"first","affiliation":[{"name":"Divisions of Viral Hepatitis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael R.","family":"Ortega-Sanchez","sequence":"additional","affiliation":[{"name":"Epidemiology and Surveillance Division, National Immunization Program, US Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"R. Douglas","family":"Scott","sequence":"additional","affiliation":[{"name":"Health Care Quality Promotion"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Rosenstein","sequence":"additional","affiliation":[{"name":"Bacterial and Mycotic Diseases, National Center for Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the ABCs Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,5,1]]},"reference":[{"key":"2021120819244128000_R1","doi-asserted-by":"crossref","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992\u20131996. J Infect Dis.\u20081999;180:1894\u20131901","DOI":"10.1086\/315158"},{"key":"2021120819244128000_R2","doi-asserted-by":"crossref","unstructured":"Scott RD, Meltzer MI, Erickson LJ, De Wals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for meningococcal disease. Am J Prev Med.\u20082002;23(2):98\u2013105","DOI":"10.1016\/S0749-3797(02)00462-2"},{"key":"2021120819244128000_R3","doi-asserted-by":"crossref","unstructured":"Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994\u20131995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis.\u20081998;4:229\u2013237","DOI":"10.3201\/eid0402.980210"},{"key":"2021120819244128000_R4","doi-asserted-by":"crossref","unstructured":"Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med.\u20082003;348:1737\u20131746","DOI":"10.1056\/NEJMoa022823"},{"key":"2021120819244128000_R5","doi-asserted-by":"crossref","unstructured":"Salisbury D. Introduction of a conjugate meningococcal type C vaccine programme in the UK. J Paediatr Child Health.\u20082001;37:S34\u2013S37","DOI":"10.1046\/j.1440-1754.2001.00738.x"},{"key":"2021120819244128000_R6","doi-asserted-by":"crossref","unstructured":"Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol.\u20082002;51:717\u2013722","DOI":"10.1099\/0022-1317-51-9-717"},{"key":"2021120819244128000_R7","doi-asserted-by":"crossref","unstructured":"Campbell JD, Edelman R, King JC, Papa T, Ryall R, Rennels MB. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diptheria toxoid conjugate vaccine given to healthy adults. J Infect Dis.\u20082002;186:1848\u20131851","DOI":"10.1086\/345763"},{"key":"2021120819244128000_R8","doi-asserted-by":"crossref","unstructured":"Lingappa JR, Rosenstein N, Zell ER, et al. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine.\u20082001;19:4566\u20134575","DOI":"10.1016\/S0264-410X(01)00209-2"},{"key":"2021120819244128000_R9","doi-asserted-by":"crossref","unstructured":"Bramley JC, Hall T, Finn A, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3, and 4 months of age. Vaccine.\u20082001;19:2924\u20132931","DOI":"10.1016\/S0264-410X(00)00528-4"},{"key":"2021120819244128000_R10","doi-asserted-by":"crossref","unstructured":"Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C vaccination in toddlers and teenagers in England. Lancet.\u20082001;357:195\u2013196","DOI":"10.1016\/S0140-6736(00)03594-7"},{"key":"2021120819244128000_R11","doi-asserted-by":"crossref","unstructured":"Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet.\u20082004;364:365\u2013367","DOI":"10.1016\/S0140-6736(04)16725-1"},{"key":"2021120819244128000_R12","doi-asserted-by":"crossref","unstructured":"Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. A Practical Guide to Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996","DOI":"10.1093\/oso\/9780195108248.001.0001"},{"key":"2021120819244128000_R13","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance. Available at: www.cdc.gov\/ncidod\/dbmd\/abcs\/abcsteam.htm. Accessed November 5, 2004"},{"key":"2021120819244128000_R14","unstructured":"Centers for Disease Control and Prevention. National Center for Health Statistics. Table 210: death rates for 113 selected causes, by 5-year age groups, race, and sex, 2000. Available at: www.cdc.gov\/nchs\/data\/dvs\/table210.pdf. Accessed November 5, 2004"},{"key":"2021120819244128000_R15","doi-asserted-by":"crossref","unstructured":"Baraff LJ, Lee SI, Schriger DL. Outcome of bacterial meningitis: a meta-analysis. Pediatr Infect Dis J.\u20081993;12:389\u2013394","DOI":"10.1097\/00006454-199305000-00008"},{"key":"2021120819244128000_R16","doi-asserted-by":"crossref","unstructured":"Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990\u20131994. Clin Infect Dis.\u20081998;26:1159\u20131164","DOI":"10.1086\/520303"},{"key":"2021120819244128000_R17","doi-asserted-by":"crossref","unstructured":"Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr.\u20081981;99:540\u2013545","DOI":"10.1016\/S0022-3476(81)80250-8"},{"key":"2021120819244128000_R18","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Fast stats A to Z: life expectancy. Available at: www.cdc.gov\/nchs\/fastats\/lifexpec.htm. Accessed November 5, 2004"},{"key":"2021120819244128000_R19","doi-asserted-by":"crossref","unstructured":"Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963\u201398: database study. BMJ.\u20082003;327:596\u2013597","DOI":"10.1136\/bmj.327.7415.596"},{"key":"2021120819244128000_R20","doi-asserted-by":"crossref","unstructured":"Thorburn K, Baines P, Thomson A, Hart CA. Mortality in severe meningococcal disease. Arch Dis Child.\u20082001;85:382\u2013385","DOI":"10.1136\/adc.85.5.382"},{"key":"2021120819244128000_R21","doi-asserted-by":"crossref","unstructured":"Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis.\u20082001;33:737\u2013739","DOI":"10.1086\/322587"},{"key":"2021120819244128000_R22","doi-asserted-by":"crossref","unstructured":"Sheridan RL, Hinson MI, Liang MH, et al. Long-term outcome of children surviving massive burns. JAMA.\u20082000;283:69\u201373","DOI":"10.1001\/jama.283.1.69"},{"key":"2021120819244128000_R23","doi-asserted-by":"crossref","unstructured":"Blakeney P, Meyer W 3rd, Robert R, Desai M, Wolf S, Herndon D. Long-term psychosocial adaptation of children who survive burns involving 80% or greater total body surface area. J Trauma.\u20081998;44:625\u2013634","DOI":"10.1097\/00005373-199804000-00011"},{"key":"2021120819244128000_R24","doi-asserted-by":"crossref","unstructured":"Holbrook TL, Hoyt DB, Anderson JP, Hollingsworth-Fridlund P, Shackford SR. Functional limitation after major trauma: a more sensitive assessment using the Quality of Well-being scale\u2013the Trauma Recovery Pilot Project. J Trauma.\u20081994;36:74\u201378","DOI":"10.1097\/00005373-199401000-00011"},{"key":"2021120819244128000_R25","doi-asserted-by":"crossref","unstructured":"Krabbe PFM, Hinderink JB, van den Broek P. The effect of cochlear implant use in postlingually deaf adults. Int J Technol Assess Health Care.\u20082000;16:864\u2013873","DOI":"10.1017\/S0266462300102132"},{"key":"2021120819244128000_R26","doi-asserted-by":"crossref","unstructured":"Neumann PJ, Sandberg PA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making.\u20082000;20:413\u2013422","DOI":"10.1177\/0272989X0002000405"},{"key":"2021120819244128000_R27","doi-asserted-by":"crossref","unstructured":"Bose A, Coen P, Tully J, Viner R, Booy R. Efficacy of meningococcal C conjugate vaccine in teenagers in England. Lancet.\u20082003;361:675\u2013676","DOI":"10.1016\/S0140-6736(03)12563-9"},{"key":"2021120819244128000_R28","doi-asserted-by":"crossref","unstructured":"Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis.\u20081999;179:1569\u20131572","DOI":"10.1086\/314753"},{"key":"2021120819244128000_R29","doi-asserted-by":"crossref","unstructured":"Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol.\u20082004;2:941\u2013945","DOI":"10.1016\/S1542-3565(04)00384-2"},{"key":"2021120819244128000_R30","doi-asserted-by":"crossref","unstructured":"Makela PH, Kayhty H, Leino T, et al. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine.\u20082003;22:287\u2013292","DOI":"10.1016\/S0264-410X(03)00524-3"},{"key":"2021120819244128000_R31","doi-asserted-by":"crossref","unstructured":"Liao S, Li R, Li H, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine.\u20081999;17:2661\u20132666","DOI":"10.1016\/S0264-410X(99)00031-6"},{"key":"2021120819244128000_R32","unstructured":"Centers for Disease Control and Prevention. National Immunization Survey. Available at: www.cdc.gov\/nip\/coverage. Accessed September 29, 2004"},{"key":"2021120819244128000_R33","unstructured":"Centers for Disease Control and Prevention. Effectiveness of a middle school vaccination law\u2014California, 1999\u20132001. MMWR Morb Mortal Wkly Rep.\u20082001;50:660\u2013663"},{"key":"2021120819244128000_R34","doi-asserted-by":"crossref","unstructured":"Lieu T, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA.\u20082000;283:1460\u20131468","DOI":"10.1001\/jama.283.11.1460"},{"key":"2021120819244128000_R35","doi-asserted-by":"crossref","unstructured":"Krause G, Blackmore C, Wiersma S, Lesneski C, Gauch L, Hopkins RS. Mass vaccination following community outbreak of meningococcal disease. Emerg Infect Dis.\u20082002;8:1398\u20131404","DOI":"10.3201\/eid0812.040421"},{"key":"2021120819244128000_R36","unstructured":"State of Hawaii Department of Health Bioterrorism Response Program. FY2005 Salary Survey. Draft report. Scottsdale, AZ: Public Sector Personnel Consultants; 2004"},{"key":"2021120819244128000_R37","unstructured":"Houck P, Patnode M, Atwood R, Powell K. Epidemiologic characteristics of an outbreak of serogroup C meningococcal disease and the public health response. Public Health Rep.\u20081995;110:343\u2013349"},{"key":"2021120819244128000_R38","doi-asserted-by":"crossref","unstructured":"Williams MO. Long-term comparison of major limb salvage using the Iliazarov method versus amputation. Clin Orthop.\u20081994;301:156\u2013158","DOI":"10.1097\/00003086-199404000-00024"},{"key":"2021120819244128000_R39","doi-asserted-by":"crossref","unstructured":"Cheng AK, Rubin HR, Powe NR, Mellon NK, Francis HW, Niparko JK. Cost-utility analysis of the cochlear implant in children. JAMA.\u20082000;284:850\u2013856","DOI":"10.1001\/jama.284.7.850"},{"key":"2021120819244128000_R40","unstructured":"Lakin KC, Polister B, Coucouvanis K, Prouty RW. Utilization of and expenditures for Medicaid institutional and home and community based services. In: Prouty RW, Smith G, Lakin KC, eds. Residential Services for Persons With Developmental Disabilities: Status and Trends Through 2002. Minneapolis, MN: University of Minnesota, Research and Training Center on Community Living, Institute on Community Integration; 2002"},{"key":"2021120819244128000_R41","unstructured":"Chambers JG, Shkolnik J, Perez M. Total expenditures for students with disabilities, 1999\u20132000: spending variation by disability. Available at: http:\/\/csef.air.org\/publications\/seep\/national\/Final_SEEP_Report_5.PDF. Accessed February 23, 2005"},{"key":"2021120819244128000_R42","doi-asserted-by":"crossref","unstructured":"Haddix AE, Teutsch SM, Corso PS, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 2003","DOI":"10.1093\/oso\/9780195148978.001.0001"},{"key":"2021120819244128000_R43","doi-asserted-by":"crossref","unstructured":"Mohr PE, Feldman JJ, Dunbar JL, et al. The societal costs of severe to profound hearing loss in the United States. Int J Technol Assess Health Care.\u20082000;16:1120\u20131135","DOI":"10.1017\/S0266462300103162"},{"key":"2021120819244128000_R44","doi-asserted-by":"crossref","unstructured":"Freed GL, Davis MM, Andreae MC. Reimbursement for Prevnar: a modern-day version of Hercules and the Hydra. Pediatrics.\u20082002;110:399\u2013400","DOI":"10.1542\/peds.110.2.399"},{"key":"2021120819244128000_R45","doi-asserted-by":"crossref","unstructured":"Zhou F, Reef S, Massoudi M, et al. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States. J Infect Dis.\u20082004;189(suppl 1):S131\u2013S145","DOI":"10.1086\/378987"},{"key":"2021120819244128000_R46","doi-asserted-by":"crossref","unstructured":"Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales. BMJ.\u20082002;324:809","DOI":"10.1136\/bmj.324.7341.809"},{"key":"2021120819244128000_R47","doi-asserted-by":"crossref","unstructured":"Kaplan B, Wandstradt TL, Cunningham JR. Overall cost in the treatment of otitis media. Pediatr Infect Dis J.\u20081997;16(2 suppl 1):S9\u2013S11","DOI":"10.1097\/00006454-199702001-00003"},{"key":"2021120819244128000_R48","doi-asserted-by":"crossref","unstructured":"Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal.\u20081995;15:369\u2013390","DOI":"10.1111\/j.1539-6924.1995.tb00330.x"},{"key":"2021120819244128000_R49","doi-asserted-by":"crossref","unstructured":"Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA.\u20081994;271:375\u2013381","DOI":"10.1001\/jama.271.5.375"},{"key":"2021120819244128000_R50","doi-asserted-by":"crossref","unstructured":"Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization: an economic analysis of current recommendations. JAMA.\u20081995;274:1201\u20131208","DOI":"10.1001\/jama.274.15.1201"},{"key":"2021120819244128000_R51","doi-asserted-by":"crossref","unstructured":"Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ.\u20082003;326:365\u2013366","DOI":"10.1136\/bmj.326.7385.365"},{"key":"2021120819244128000_R52","doi-asserted-by":"crossref","unstructured":"Maiden MCJ, Stuart JM, UK Meningococcal Carriage Group. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet.\u20082002;359:1829\u20131830","DOI":"10.1016\/S0140-6736(02)08679-8"},{"key":"2021120819244128000_R53","doi-asserted-by":"crossref","unstructured":"Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med.\u20082001;344:1378\u20131388","DOI":"10.1056\/NEJM200105033441807"},{"key":"2021120819244128000_R54","doi-asserted-by":"crossref","unstructured":"Hume SE. Mass voluntary immunization campaigns for meningococcal disease in Canada: media hysteria. JAMA.\u20081992;267:1833\u20131838","DOI":"10.1001\/jama.1992.03480130153046"},{"key":"2021120819244128000_R55","doi-asserted-by":"crossref","unstructured":"Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Ann Rev Med.\u20082004;55:333\u2013353","DOI":"10.1146\/annurev.med.55.091902.103612"},{"key":"2021120819244128000_R56","doi-asserted-by":"crossref","unstructured":"Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment, and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J.\u20081996;15:967\u2013979","DOI":"10.1097\/00006454-199611000-00009"},{"key":"2021120819244128000_R57","doi-asserted-by":"crossref","unstructured":"Barquet N, Domingo P, Cayla JA, et al. Meningococcal disease in a large urban population (Barcelona, 1987\u20131992): predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group. Arch Intern Med.\u20081999;159:2329\u20132340","DOI":"10.1001\/archinte.159.19.2329"},{"key":"2021120819244128000_R58","doi-asserted-by":"crossref","unstructured":"Bohr V, Hansen B, Kjersem H, et al. Sequelae from bacterial meningitis and their relation to the clinical condition during acute illness, based on 667 questionnaire returns. Part II of a three part series. J Infect.\u20081983;7:102\u2013110","DOI":"10.1016\/S0163-4453(83)90443-7"},{"key":"2021120819244128000_R59","doi-asserted-by":"crossref","unstructured":"Postma A, Kingma A, De Ruiter J, et al. Quality of life in bone tumor patients comparing limb salvage and amputation of the lower extremity. J Surg Oncol.\u20081992;51:47\u201351","DOI":"10.1002\/jso.2930510113"},{"key":"2021120819244128000_R60","doi-asserted-by":"crossref","unstructured":"Tennvall GR, Apelqvist J. Health-related quality of life in patients with diabetes mellitus and foot ulcers. J Diabetes Complications.\u20082000;14:235\u2013241","DOI":"10.1016\/S1056-8727(00)00133-1"},{"key":"2021120819244128000_R61","unstructured":"Centers for Disease Control and Prevention. National, state, and urban area vaccination levels among children aged 19\u201335 months\u2014United States, 2002. MMWR Morb Mortal Wkly Rep.\u20082003;52:728\u2013732"},{"key":"2021120819244128000_R62","unstructured":"Centers for Disease Control and Prevention. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment\u2014United States, 2003. MMWR Morb Mortal Wkly Rep.\u20082004;53:57\u201359"},{"key":"2021120819244128000_R63","unstructured":"Centers for Disease Control and Prevention. CDC vaccine price list. Available at: www.cdc.gov\/nip\/vfc\/cdc_vac_price_list.htm. Accessed November 5, 2004"},{"key":"2021120819244128000_R64","unstructured":"Roswell Pediatric Center. Menommune: \u201cthe meningococcal vaccine.\u201d Available at: www.roswellpediatrics.com\/menommune.htm. Accessed November 5, 2004"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/5\/1220\/1028649\/zpe00505001220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/5\/1220\/1028649\/zpe00505001220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T13:29:54Z","timestamp":1706189394000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/5\/1220\/67508\/Cost-Effectiveness-of-Conjugate-Meningococcal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2005,5,1]]},"published-print":{"date-parts":[[2005,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2514","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,1]]}}}